AirSculpt Technologies Names Mike Doyle as Non-Executive Board Chairman

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Nov 17 2025

0mins

AIRS-11.69%

Should l Buy AIRS?

Source: Newsfilter

Appointment of New Chairman: AirSculpt Technologies has appointed Mike Doyle as the Non-Executive Chairman of its Board of Directors, bringing over 30 years of experience in the multi-center healthcare sector.
Leadership Experience: Doyle has a strong background in scaling healthcare organizations, having previously served as CEO of Surgery Partners and held leadership roles in various healthcare boards.
CEO's Statement: Yogi Jashnani, CEO of AirSculpt, expressed enthusiasm about Doyle's appointment, highlighting his experience in partnering with surgeons and developing new service lines.
About AirSculpt: AirSculpt offers a next-generation body contouring treatment that is minimally invasive, focusing on comfort and precision, with quick healing and minimal bruising.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy AIRS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on AIRS

About AIRS

AirSculpt Technologies, Inc., through its wholly owned subsidiaries, is a provider of practice management services to professional associations (PAs) located throughout the United States, Canada, and the United Kingdom. The Company owns and operates non-clinical assets and provides its management services to the PAs through management services agreements (MSAs). It operates through the direct medical procedure services segment. The Company offers fat removal procedures across treatment areas. It also offers fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips, or other areas and do not require silicone or foreign materials to be implanted. Its body contouring procedures include the Power BBL, a Brazilian butt lift procedure, the Up a Cup, a breast enhancement procedure, and the Hip Flip, an hourglass contouring procedure. Its AirSculpt + procedure permanently removes fat and tightens the skin with unparalleled precision and finesse.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

NASDAQ 100 Pre-Market Indicator Rises Significantly

Mar 16 2026NASDAQ.COM

Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator rises by 266.97 points to 24,647.7, indicating a positive shift in market sentiment that may attract more investors to tech stocks.
Active Stock Performance: CytomX Therapeutics, Inc. (CTMX) increases by $2.34 to $7.02 with a trading volume of 27,793,236 shares, reflecting optimistic short-term prospects for the company.
ETF Trading Dynamics: ProShares UltraPro QQQ (TQQQ) climbs $1.46 to $47.39 with 6,584,506 shares traded, representing a 170.8% increase from its 52-week low, showcasing strong investor interest in tech stocks.
Earnings Forecast Revisions: Circle Internet Group, Inc. (CRCL) rises $5.795 to $121.18, with an expected EPS of $0.22 for the fiscal quarter ending September 2026, indicating market confidence in its future profitability.

Zeta Global Surpasses Quarterly Earnings Expectations

Feb 25 2026NASDAQ.COM

Earnings Beat: Zeta Global Holdings reported earnings of $0.28 per share, exceeding the Zacks Consensus Estimate of $0.23, reflecting a 40% increase from last year's $0.20, indicating a significant improvement in profitability.
Significant Revenue Growth: The company posted revenues of $394.64 million for the quarter, surpassing the Zacks Consensus Estimate of $380 million and marking a 25.4% increase from $314.67 million a year ago, demonstrating strong market demand.
Underperformance in Market: Despite exceeding earnings expectations, Zeta's stock has declined approximately 26.4% since the beginning of the year, compared to a 0.1% drop in the S&P 500, reflecting investor concerns about the company's future performance.
Cautious Outlook: With a current Zacks Rank of 3 (Hold), investors are cautious about earnings expectations for the upcoming quarters, especially given the Technology Services industry's ranking in the bottom 38%.

Friday's Underperforming Sectors: Construction, Healthcare, and Medical Professionals

Dec 05 2025NASDAQ.COM

Market Performance: Hospital and medical practitioners' shares are down approximately 1.7% on Friday, with Agilon Health and AirSculpt Technologies leading the decline at 9% and 8.3%, respectively.
Sector Laggards: The construction sector, along with hospital and medical practitioners, is identified as a laggard in the market on Friday.
Video Coverage: A video segment highlights the performance of these sectors, focusing on the laggards in the market.
Author's Perspective: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.

Three Health Care Stocks That Could Revitalize Your Portfolio This November

Nov 18 2025Benzinga

Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.